# Nurr1 Activator Vidofludimus Calcium Exhibits Signs of **Neuroprotection in Preclinical Models**



<u>E. Peelen</u><sup>1</sup>, H. Wu<sup>2</sup>, M. Jafari<sup>1</sup>, T. Wulff<sup>1</sup>, C. Gege<sup>1</sup>, A. Herrmann<sup>3</sup>, A. Muehler<sup>1,4</sup>, D. Vitt<sup>4</sup>, Z. Sun<sup>2</sup>, H. Kohlhof<sup>1</sup>


<sup>1</sup>Immunic AG, Graefelfing, Germany;

<sup>2</sup> Beckman Research Institute of City of Hope, Department of Immunology & Theranostics, Duarte, United States; <sup>3</sup> former employee of Immunic AG, Graefelfing, Germany <sup>4</sup> Immunic Inc., New York, United States




#### 1. Background

Nuclear receptor-related 1 (Nurr1), a transcription factor, regulates genes that enhance neuronal survival and reduces neurotoxic mediators produced by microglia and astrocytes<sup>1-3</sup>. Growing evidence supports its protective role in neurodegenerative diseases<sup>4</sup>. In persons with multiple sclerosis (PwMS), Nurr1 gene expression in blood was reduced<sup>5</sup>. Fingolimod is the sole disease modifying therapy tested that showed increased Nurr1 mRNA levels in peripheral immune cells of PwMS<sup>6,7</sup>. However, this increase was only observed after 2 years of treatment<sup>7</sup>. Here, the potential Nurr1 activity of vidofludimus calcium (VidoCa), currently in phase 2 and 3 clinical trials for progressive and relapsing MS, respectively, was assessed in vivo. VidoCa has a dual mode of action, functioning both as as a potent Nurr1 activator and a next generation DHODH inhibitor.



= Aromatic L-amino acid decarboxylase: BDNF = brain derived neurotrophic factor; COX5b cytochrome c oxidase subunit 5B; DAT = dopamine transporter: DHODH dihydroorotate dehydrogenase; GDNF = Glial cell line-derived neurotrophic factor; IL-1 $\beta$  = interleukin 1 beta; MBP = myelin basic protein; NO = Nitric oxide; ROS = Reactive oxygen species; SOD1 = superoxide dismutase 1; Th = tyrosine hydroxylase; TNF $\alpha$  = Tumor necrosis factor alpha: TSFM = Ts factor, mitochondrial: VMAT2 =

#### 2. Methods




Schematic overview of the EAE studies

| Treatment                              | Dose      | Model                                 | Readouts            | Pilot            | Prophylactic      | Therapeutic        |
|--|-----------|---------------------------------------|---------------------|------------------|-------------------|--------------------|
| Vehicle (PEG400)                       | -         | all                                   | Disease (EAE) score | <b>✓</b> (n = 4) | <b>✓</b> (n = 15) | <b>✓</b> (n =      |
| VidoCa                                 | 150 mg/kg | all                                   |                     |                  |                   | 14/15)             |
| Reference (FTY720)                     | 5 mg/kg   | Therapeutic                           | FACS                |                  | <b>✓</b> (n = 8)  | <b>✓</b> (n = 7/8) |
| (* * * * * * * * * * * * * * * * * * * | 56/6      | · · · · · · · · · · · · · · · · · · · | RT-qPCR (brain, SC) |                  | <b>✓</b> (n = 7)  | <b>✓</b> (n = 7)   |
|  |           |                                       | Plasma NfL          |                  | <b>✓</b> (n = 15) |                    |
|  |           |                                       | Heart Plasma BDNF   |                  | <b>✓</b> (n = 15) |                    |
|  |           |                                       | Histology           | <b>✓</b> (n = 4) |                   |                    |

BDNF = brain derived neurotrophic factor; CFA = Complete Freund's Adjuvant; d.p.i. = days post immunization; EAE = experimental autoimmune FACS = fluorescence-activated cell sorting; FTY720 = fingolimod; MOG = myelin oligodendrocyte glycoprotein; NfL = neurofilament light chain; p.o. =


## 3. VidoCa Attenuates Disease Severity in EAE Models



VidoCa attenuates disease severity in both prophylactic and therapeutic murine EAE models. In the prophylactic EAE model, mice treated with VidoCa showed lower disease severity as well as a 0.22-fold lower relative risk (HR) of developing symptoms compared to mice treated vehicle. Reducing disease severity by VidoCa was also shown in a therapeutic model, to a similar extent as FTY720 treatment.

vs post immunization; FTY720 = fingolimod (reference); HR = hazard ratio; Data in the graphs are shown as mean + SEM. Statistics: (A,C) two-way


### 4. VidoCa Reduces T Lymphocyte Infiltration into the CNS



VidoCa reduces T helper (Th) cell infiltration into the CNS in murine EAE models. In the therapeutic model VidoCa shows similar activity in reducing Th cell infiltration as the reference treatment (FTY720).

CNS = central nervous system;. Data in the graphs are shown as mean + SEM. Statistics: (A-C) two-tailed t-test, (D-E) one-way ANOVA followed by Dunnett's


# 5. VidoCa Increases Expression of Nurr1 Target Genes In Vivo



VidoCa treatment augments Nurr1-regulated gene expression in the CNS in both prophylactic and therapeutic EAE models. The regulation of these genes seems different compared to the reference treatment (FTY720). These data support the potential activation of Nurr1 by VidoCa in vivo.

FTY720 = fingolimod; Nr4a2 = nuclear receptor subfamily 4 group A member 2; Nurr1 = nuclear receptor 1; SC = spinal cord; Sod1 = superoxide dismutase 1; Th = tyrosine hydroxylase; Data in the graphs are shown as mean + SEM. Statistics: (A-C) two-tailed t-test: (D-F) one-way ANOVA followed by Dunnett's multiple comparisons test. \*p<0.05: \*\*p<0.01


# 6. VidoCa Displays Neuroprotective Potential in EAE



VidoCa displays neuroprotective activity in vivo in an EAE model. Prophylactic treatment with VidoCa increased plasma BDNF levels, a potential peripheral biomarker for Nurr1 activation, and reduced plasma NfL levels, a biomarker for axonal damage and neurodegeneration. These data indicate that VidoCa activates Nurr1 in vivo and support its potential neuroprotective activity. This is further supported by a higher myelin (MBP) content, a tendency towards lower microglial activation (IBA1) and axonal injury (APP) in the spinal cord in a small prophylactic pilot EAE study.

APP = amyloid precursor protein; BDNF = brain derived neurotrophic factor; IBA1 = ionized calcium-binding adaptor molecule 1; MBP = myelin basic protein; Statistics: two-tailed t-test.

# 7. Overview and Conclusions



# VidoCa

- > Reduces disease severity and immune cell infiltration into the CNS in EAE
- Activates Nurr1 in vitro and in vivo
- > Displays neuroprotective effects in vitro and in vivo, most likely mediated by **Nurr1-driven regulation of survival signals**
- > Offers the potential to treat both relapsing and progressive forms of MS, due to its dual mode of action

Disclosure

# Contact: evelyn.peelen@imux.com

- Vietor et al., 2023, J Med Chem, 66, 6391 <sup>2</sup> Schirò et al., 2022, Front Neurol, 13, 917527 <sup>3</sup> Saijo et al., 2009, Cell, 137, 47 <sup>1</sup> Pansieri et al., 2023, Brain Comms, 5, 1
- <sup>6</sup> Gilli et al., 2011, Arch Neurol, 68, 879 <sup>7</sup> Montarolo et al., 2018, Eur J Neurol, 0, 1
- <sup>9</sup> Chen et al., 2018, CNS Neurosci Ther, 24, 790 <sup>10</sup> Al-Nusaif et al., 2022, Int J Mol Sci, 23, 16184
- <sup>11</sup> Berneda-Zahonero et al. J Bio Chem, 287, 11351
- This project was funded by Immunic Therapeutics. E.P., A.H., T.W., M.J., C.G., and H.K. are employees of Immunic AG, holding shares and/or stock options of the parent company, Immunic, Inc.. A.M. and D.V. are employees of Immunic AG and Immunic Inc. and are shareholders of Immunic Inc.. E.P., C.G. A.M., D.V., and H.K. are inventors on a patent application covering the topic. The work of Z.S. and H.W. is supported by Immunic AG.

# References